How Glucagon Is Stored: Stability and Handling, Per the Research

Storage questions about glucagon are really questions about a single chemical fact: glucagon is awkward to keep in water. Most of the handling conventions attached to glucagon products — dry powder in one vial, diluent in another, mixing immediately before administration — exist because of that fact rather than because of anything unusual about the hormone's biology. This page separates what glucagon-specific formulation literature reports from what is general lyophilized-peptide stability science, and says which is which in each section. It is descriptive only. For the broader framework that applies across peptides, see how to store peptides; for background on the molecule itself, see glucagon.

This page is for educational purposes only and is not medical advice; consult a licensed physician or pharmacist about any medicine, its labelling, or its handling.

Glucagon in one paragraph

Glucagon is the pancreatic counter-regulatory hormone to insulin and acts chiefly on the liver, where it drives the release of stored glucose. A 2012 review in The Biochemical Journal described glycogen and its metabolism, including the regulated breakdown of hepatic glycogen stores that supplies circulating glucose (PMID 22248338), and a biochemistry overview summarised glycogen structure, synthesis and mobilisation in the liver and muscle (PMID 30969624). A 2006 paper reported on glycogen autophagy as a contributor to glucose homeostasis (PMID 16781826), and a 2025 Nature Communications study reported non-catalytic mechanisms by which KMT5C regulates hepatic gluconeogenesis, the other liver pathway that raises blood glucose (PMID 39929827). None of that physiology changes with storage conditions. What storage determines is whether the peptide presented to the receptor is still the intact peptide.

Why glucagon is a hard peptide to keep in solution

Glucagon-specific literature. A 2024 review in the International Journal of Pharmaceutics surveyed delivery advancements for glucagon in hypoglycaemia management and reported that the peptide's poor aqueous solubility and its tendency to aggregate and form fibrils in solution have been the central obstacles to developing stable, ready-to-use glucagon products (PMID 38224759). That same review described how the field responded — non-aqueous solvents, stabilising excipients, alternative delivery routes and analogue chemistry — rather than by simply refrigerating a conventional aqueous solution (PMID 38224759).

A 2021 review in Science Translational Medicine on engineering biopharmaceutical formulations for diabetes management reported that formulation science — excipient selection, solvent systems and molecular modification — has been the principal lever for improving the physical and chemical stability of peptide drugs used in glucose management (PMID 33504649). In other words, the stability of a glucagon product is a property of the formulation, not of the amino-acid sequence alone, which is why storage statements differ between presentations.

Lyophilized powder versus reconstituted solution

The traditional emergency glucagon presentation is a lyophilized (freeze-dried) powder packaged with a separate diluent. The 2024 delivery review described this reconstitute-immediately-before-use format as the long-standing standard for glucagon, and discussed newer ready-to-use liquid and nasal powder presentations developed to remove the mixing step (PMID 38224759).

General lyophilized-peptide science, not glucagon-specific: freeze-drying removes the water that participates in hydrolysis, deamidation and aggregation. A dry cake is therefore typically the most stable state a peptide occupies, and reconstitution starts a much shorter clock. This is standard pharmaceutical chemistry rather than a finding from any single trial, and the practical consequence is that "how long does glucagon last" has two different answers depending on whether the vial is dry or wet.

Does glucagon need refrigeration?

The honest answer from the literature is: it depends on the presentation, and the labelling for each product is the governing document. Approved glucagon products are not a single thing. The 2024 review reported that glucagon is now available across multiple delivery formats — conventional reconstituted kits, ready-to-use liquid autoinjectors and pens, and intranasal powder — each developed with its own formulation chemistry (PMID 38224759). Those formats do not share a single storage statement.

Two conventions are worth defining, because they are labelling definitions rather than study findings: pharmacopeial "refrigerated" storage is conventionally 2–8 °C, and "controlled room temperature" is conventionally around 20–25 °C with brief excursions permitted. Those figures are regulatory conventions, not results reported by any paper on this page's citation list.

What the research literature adds is the reason refrigeration is not automatically protective for glucagon. Because the dominant degradation pathway described for glucagon in solution is physical aggregation and fibril formation rather than simple thermal breakdown (PMID 38224759), cold storage is not a universal fix; a formulation engineered for room-temperature stability may be designed around a non-aqueous solvent system instead, a strategy the 2021 formulation review discussed in the context of diabetes biopharmaceuticals generally (PMID 33504649).

Shelf life, expiry dating and what the date actually means

General principle, not a study finding: an expiry date is the end of the period over which the manufacturer has generated stability data showing the product remains within specification under the storage conditions printed on the label. It is a tested guarantee window, not a point at which a molecule transforms. The corollary is that the date is only meaningful if the stated conditions were maintained — a product kept outside its labelled range has, in effect, left the conditions the dating was established under.

For glucagon specifically, the reconstituted state is the short-lived one. The 2024 review framed the entire push toward ready-to-use and non-injectable glucagon as an effort to remove the reconstitution step and its handling burden from emergency use (PMID 38224759), which indirectly tells the reader how limited the in-use window for a mixed conventional kit has traditionally been considered.

Room temperature and travel

Mostly general science. Peptide degradation rates rise with temperature, so the variables that matter in transit are peak temperature, cumulative time at that temperature, and mechanical agitation. For glucagon the agitation variable carries extra weight: because the peptide's characteristic failure mode in solution is aggregation and fibrillation (PMID 38224759), shaking and air–liquid interface exposure are recognised aggregation triggers for peptides of this class in general formulation science. Dry lyophilized cake is comparatively robust to agitation; reconstituted solution is not.

Ready-to-use presentations were specifically developed, per the 2024 review, so that a stable glucagon dosage form could be carried and deployed without on-the-spot mixing (PMID 38224759). Their permitted temperature ranges and excursion allowances are product-specific labelling facts.

Freezing and freeze–thaw

General lyophilized-peptide science. Freezing a reconstituted peptide solution concentrates solutes in the unfrozen fraction, shifts pH as buffer components crystallise, and creates new ice–water interfaces — all recognised drivers of aggregation. Repeated freeze–thaw cycling compounds the effect. For a peptide whose published formulation problem is aggregation (PMID 38224759), freeze–thaw is the opposite of a conservative handling choice. An already-lyophilized cake is a different case: it contains little free water, and the relevant risk in a freezer is usually moisture ingress through an imperfect seal rather than ice formation.

Degradation signs and handling failures: What Studies Report

The glucagon formulation literature describes degradation primarily as a physical event. The 2024 review reported that fibril formation and aggregation in aqueous glucagon have been the key stability-limiting phenomena that formulators have worked to prevent (PMID 38224759). Physically, aggregation of a peptide solution is what produces visible changes — haze, cloudiness, visible strands or particulates, or a gel-like consistency.

Two cautions follow from that, both well established in general formulation science rather than specific to any one paper:

• Visible change is a late signal. Chromatographic and spectroscopic assays detect chemical degradation long before anything is visible to the eye. A clear solution is not evidence of an intact one.
• Absence of visible change proves nothing about potency. Stability programmes measure potency analytically precisely because appearance is an unreliable surrogate; the 2021 review framed formulation engineering as the discipline that keeps measured stability within specification across a shelf life (PMID 33504649).

The clinically relevant consequence of aggregation in an emergency product is loss of deliverable, active drug at the moment it is needed — which is the problem the ready-to-use and intranasal formats described in the 2024 review were built to address (PMID 38224759).

Shelf stability is not the same as stability in the body

These two ideas are routinely conflated. Stability in vivo is about enzymatic clearance; stability on the shelf is about chemistry in a vial. A 2007 review of incretin biology reported that GLP-1 and GIP are rapidly degraded in circulation by dipeptidyl peptidase-4 (PMID 17498508) — an enzymatic problem that no refrigerator addresses. The semaglutide discovery paper reported that structural modification, including a fatty diacid side chain conferring albumin binding, produced a GLP-1 analogue suitable for once-weekly administration (PMID 26308095), and a 2018 Science Translational Medicine study reported that co-formulation with the absorption enhancer SNAC enabled transcellular stomach absorption of a derivatised GLP-1 receptor agonist (PMID 30429357). Those are molecular-design and absorption findings, not storage findings, and they do not transfer to glucagon handling.

Evidence map: glucagon-specific versus general

What a storage rule can and cannot establish

A labelled storage condition establishes the envelope within which a manufacturer's stability data apply. It does not establish that a product outside that envelope has failed, nor that one inside it is potent — only that the tested evidence covers one case and not the other. For glucagon, the literature's clearest message is structural: the historical handling conventions exist because aqueous glucagon aggregates, and the newer formats exist because formulators found ways around that (PMID 38224759, PMID 33504649). Anything more specific than that belongs to the individual product's approved labelling and to a pharmacist or physician reading it.

Related reading

• Peptide storage and stability: the general framework
• Glucagon: what the literature covers

References

• Glucagon: Delivery advancements for hypoglycemia management (International Journal of Pharmaceutics, 2024)
• Engineering biopharmaceutical formulations to improve diabetes management (Science Translational Medicine, 2021)
• Glycogen and its metabolism: some new developments and old themes (The Biochemical Journal, 2012)
• Biochemistry, Glycogen (StatPearls)
• Glycogen autophagy in glucose homeostasis (Pathology, Research and Practice, 2006)
• Non-catalytic mechanisms of KMT5C regulating hepatic gluconeogenesis (Nature Communications, 2025)
• Biology of incretins: GLP-1 and GIP (Gastroenterology, 2007)
• Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide (Journal of Medicinal Chemistry, 2015)
• Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist (Science Translational Medicine, 2018)